In this CRO Report, we provide tailwinds driving growth in the industry, an industry analysis, public comparables and precedent transactions, active buyers in the market, and explore the recent and impressive funding levels in Biopharma.
This report includes:
- CRO Market Size and Market Share
- Public Comparables – Charles River Laboratories International vs. Index
- Public Company Performance & Multiples, and Precedent Transactions
- Funding Levels in Biopharma including Venture Funding, IPO Funding, and Follow-On Funding
- Active Strategic Acquirers, and Private Equity Buyers in the Market
- Recent CRO Transactions from Q3 19 to Present
If you are interested in discussing any of the analysis from this report, or if you would like to discuss your own transaction goals contact Managing Director David Crean below, or reach out at (800) 849-7010 or [email protected] to be directed to the appropriate team member.
About the Author:
This news release is for informational purposes only and does not constitute an offer, invitation or recommendation to buy, sell, subscribe for or issue any securities. While the information provided herein is believed to be accurate and reliable, Objective Capital Partners and BA Securities, LLC make no representations or warranties, expressed or implied, as to the accuracy or completeness of such information. All information contained herein is preliminary, limited and subject to completion, correction or amendment. It should not be construed as investment, legal, or tax advice and may not be reproduced or distributed to any person. Securities and investment banking services are offered through BA Securities, LLC Member FINRA, SIPC. Principals of Objective Capital are Registered Representatives of BA Securities. Objective Capital Partners and BA Securities are separate and unaffiliated entities.